A Multi-Cohort Phase 1b Clinical Trial of Rituximab in Combination With Immunotherapy in Untreated and Previously Treated Follicular Lymphoma
Latest Information Update: 10 Feb 2025
At a glance
- Drugs Avelumab (Primary) ; Ivuxolimab (Primary) ; Rituximab (Primary) ; Utomilumab (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 06 Feb 2025 No. of study arms increased from 3 to 7. Timeframe for primary endpoints has been changed.
- 06 Feb 2025 Status changed from active, no longer recruiting to discontinued.
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition